News

PTC Therapeutics, Inc. announced that their collaborative program with Roche and the SMA Foundation (SMAF) for Spinal Muscular Atrophy (SMA) has begun its second phase with adult and children patients, as part of the Phase 1b/2a study. The program is evaluating the safety and tolerability of an under-investigation drug – survival of…

This year, Cure SMA granted the 2014 SMA Breakthrough Award to Isis Pharmaceuticals at the Cure SMA Gala of Hope, which took place in Seal Beach, California. The award was granted to the company in recognition of their work and efforts to improve treatment of spinal muscular atrophy (SMA), the leading genetic cause of…

While SMA is a rare disease that many people are unaware of, an active network of advocacy groups work worldwide to raise funds and awareness about the disease. As part of this effort, the Angel Gala in Canada will continue its legacy of supporting spinal muscular atrophy (SMA)…

A study entitled “Patient with spinal muscular atrophy with respiratory distress type 1 presenting initially with hypertonia” reports a case study of a two-month-old boy with spinal muscular atrophy with respiratory distress type 1 that displayed hypertonia as an initial symptom and progressing to bone tissue compromise, a new symptom that has…

Next Saturday, November, 8, Santa Barbara will host dozens of racers and walkers to raise both awareness and funds to support Spinal Muscular Atrophy (SMA) patients, at the annual Santa Barbara Veteran’s Day Marathon and Half Marathon. Gwendolyn Strong, a 7-year-old patient and the beneficiary of the event, dubbed the Gwendolyn…

Isis Pharmaceuticals received a $5 million milestone payment from partner GlaxoSmithKline following news of its investigational drug ISIS-GSK5Rx being granted the development candidate designation. ISIS-GSK5Rx is the second medication created as a result of the collaboration between the two companies and is an antisense drug, indicated for the treatment of an undisclosed ocular disease. Among other…